Coming Soon: Conexiant’s news site is becoming MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more.
Infectious Disease
Partner With Us
Advertisement
Conexiant chevron_right Infectious Disease chevron_right DOOR framework shows similar outcomes in skin infection trials
From the Journals

DOOR framework shows similar outcomes in skin infection trials

“Using DOOR can provide clinicians and patients with a better understanding of the benefits and risks of new anti-infectives being studied to treat skin infections.” 

MDSpire News

Clinical Scorecard: DOOR framework shows similar outcomes in skin infection trials

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: DOOR framework shows similar outcomes in skin infection trials
Key MechanismsDesirability of outcome ranking (DOOR) framework evaluates treatment benefits and harms in the context of the trials.
Target PopulationPopulation described in the source article.
Care SettingCare setting described in the source article.

Key Highlights

  • Subgroup analysis indicated a potential benefit of omadacycline in patients with diabetes, but this finding is hypothesis-generating due to the small sample size.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider both omadacycline and linezolid as treatment options based on patient-specific factors, as indicated in the trials.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Participants from OASIS-1 and OASIS-2 trials, totaling 1,347 patients.

        Both treatments were effective, with no significant differences in outcomes.

        Clinical Best Practices

        • Incorporate DOOR framework in future ABSSSI trials for comprehensive outcome assessment, as suggested by the authors.

        Related Resources & Content

        Daily News

        Stay up to date with the latest clinical headlines and other information tailored to your specialty.